NTRA Trading Analysis - 11/04/2026 04:43 PM — TRU-SENTIMENT

News Headlines & Context

Based on general knowledge of NTRA (Natera, Inc.), a molecular diagnostics company focused on cell-free DNA testing:

• Recent coverage has highlighted Natera's expansion in oncology testing volumes and reimbursement wins for its Signatera MRD assay, a potential long-term catalyst for revenue.
• The company has historically operated at a net loss; ongoing debates around profitability timeline and cash burn remain key concerns for investors.
• No specific earnings date is flagged in the provided data, but fiscal year end is listed as 2025-12-01, with next major options expiration on 2026-12-18.
• Broader diagnostic sector has seen volatility from policy and reimbursement uncertainty, which may amplify NTRA's beta of 1.89.
• Context: The embedded data shows a sharp drop on 2026-11-02 (close $380.72 from open $418.41) and weak options sentiment, suggesting recent news flow or positioning may lean cautious despite fundamental growth narratives.

Fundamental Analysis

From the provided FUNDAMENTALS data (source: FinWin fundamentals, local):

• Trailing EPS is -1.35; company is not profitable (no trailing PE, forward PE null, PEG null).
• Market cap is $56.36B with 144.14M shares outstanding; dividend yield 0.0% (no dividend).
• Beta is 1.89 (highly volatile vs market); 52-week range $181.00 to $437.41 (current $387.04 within range).
• Institutional ownership 69.31%; average volume 1.67M shares.
• Historical volatility 46.37%; no revenue, margin, ROE, D/E, or FCF data provided (all null).
• Analyst target mean price and consensus are null; no sell-side guidance in data.
• Alignment: Fundamentals show a loss-making high-beta biotech with no valuation multiples; this diverges from technicals where price sits above 50-day SMA but below 5/20-day SMAs, and from bearish options sentiment.

Current Market Position

Current price per indicators: $387.04 (2026-11-04 close). Daily history shows:

Minute bars (last 5 of 156): 2026-11-04 15:55 close $390.49 on volume 158,682 (spike vs prior ~25k), showing late-session bounce from low $385.45. Intraday trend was downward most of session (open $393.42, low $369.51) then recovery.

Key levels from data: 30-day low $369.51, 30-day high $437.41; Bollinger lower $376.90, middle $402.42, upper $427.94; SMA50 $380.23.

Technical Analysis

Price is below SMA5 ($400.78) and SMA20 ($402.42) but above SMA50 ($380.23) — short-term bearish alignment, long-term supportive. No golden/death cross explicit, but 5/20 below price previously; now price dropped under them.

RSI 43.22 = neutral-to-soft momentum, no oversold. MACD positive (3.90 > signal 3.12, hist 0.78) = mild bullish momentum despite price weakness. Bollinger: price near lower band ($376.90), expanded range. 30-day range: price at $387.04 is 15.1% above low, 11.5% below high.

True Sentiment Analysis (Delta 40-60 Options)

From True Sentiment options data (methodology: Delta 40-60 only):

Call Volume: $95,120 (5.5%) Put Volume: $1,649,120 (94.5%) Total: $1,744,240

Sentiment: Bearish. 29 call contracts vs 532 put contracts. Pure directional conviction heavily put-sided (94.5% put dollar vol). Near-term expectations lean defensive/bearish.

Divergence: Technicals show MACD mild bullish and price above SMA50, but options flow is aggressively bearish — confirmed by spread recommendation "no_recommendation" due to divergence.

Key Price Levels (observational only)